New UK Vaccine Research & Testing Center Targets Pandemic Pathogens
Executive Summary
A new UK center is to work with the pharmaceutical industry and international regulators on the development and evaluation of vaccines against future pandemic agents, and has a potential vaccine against Crimean-Congo hemorrhagic fever in Phase I trials. The center is expected to play a key role in helping the global “100 Days Mission” achieve its aim of accelerating the availability of new medical countermeasures in future health crises.
You may also be interested in...
Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package
The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.
EU Bodies Agree On Ways To Future-Proof EMA Funding System
EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.
Coronavirus Notebook: UN Pandemic Declaration Disappoints, Focus Turns To Draft WHO Treaty
The World Health Organization has published a “step-by-step guide” for countries wishing to increase their capacity for monitoring pathogens with pandemic and epidemic potential. The EU and the UK have cleared an updated version of Moderna’s COVID-19 vaccine Spikevax targeting the XBB.1.5 variant, while the EU has followed the US in approving Gilead’s Veklury as the first treatment for COVID-19 patients with mild-to-severe liver damage.